Sphingomonas paucimobilis is a glucose-nonfermenting Gram-negative bacillus that is widely distributed in both natural environment and hospitals. Various infections in humans have been reported, but most have been limited to sporadic case reports. The aim of this study was to describe the clinical characteristics and manifestations of S. paucimobilis bacteremia. We also reviewed the literature on S. paucimobilis bacteremia. METHODS: Cases of S. paucimobilis bacteremia were identified retrospectively at a university-affiliated hospital in Taiwan. In addition, relevant case reports were identified through PubMed and reviewed. RESULTS: From April 2004 to April 2008, 42 cases of S. paucimobilis bacteremia were identified in this study. Among them, 16 cases were identified from E-Da hospital, Kaohsiung, Taiwan and 26 cases from the literature review. The median age of patients was 48.5 years and 57.1% were male. The most common comorbidities included malignancy (57.1%), immunosuppressant use (40.5%), and diabetic mellitus (11.9%). Hospital-acquired bacteremia accounted for 69.0% of infections. Primary bacteremia and catheter-related bloodstream infection were found in 35.7% and 33.3% respectively. The most effective antibiotics were fluoroquinolones, carbapenems, and β-lactam/β-lactamase inhibitor combinations. All 42 patients survived the S. paucimobilis bacteremic episodes, but three patients experienced septic shock.
Definition of bacteremia
Hospital-acquired bacteremia was defined by at least one positive blood culture for S. paucimobilis taken at least 72 hours after admission in patients without clinical evidence of septicemia on presentation. Community-acquired bacteremia was defined in patients that developed bacteremia within 72 hours of hospitalization. The source of bacteremia was determined on the basis of clinical findings or bacterial culture results. Bacteremic episodes without concurrent infectious foci were considered as primary bacteremia. Types of indwelling intravascular devices included the central venous pressure catheter, Hemo-Cath, Port-A-Cath, Hickman catheter, Dacron graft, Groshong catheter, and arterial line. Catheter-related bacteremia was diagnosed according to the standard definitions of catheterrelated infections: (1) isolation of the same microorganism from blood and exudates from the catheter exit site or specimens from the catheter lumen in the presence of signs of inflammation; and (2) isolation of the same microorganism from blood and the catheter tip on removal of the catheter. 29 Shock was defined as systolic blood pressure < 90 mmHg or requiring inotropic agents to maintain blood pressure. Immunosuppressant use was defined as the utilization of cytotoxic agents for cancer, before bone marrow transplantation, or the use of corticosteroids (> 30 mg prednisolone daily or 1 week). We defined antibiotic therapy as inappropriate if an antibiotic agent active against S. paucimobilis (as determined by in vitro susceptibility testing) at the usual recommended dosage was
Introduction
Sphingomonas paucimobilis, formerly known as Pseudomonas paucimobilis, is a yellow-pigmented, glucose-nonfermenting, strictly aerobic, Gram-negative bacillus with a single polar flagellum. It is categorized as CDC group IIk biotype 1, 1 and it was initially reported to be a human pathogen in 1979.
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The natural habitat of this organism has not been fully defined but it is known to be widely distributed in the natural environment, particularly in water and soil, and has also been isolated from hospital settings, including hospital water systems, distilled water, dialysis fluid, nebulizers, and other respiratory therapy equipment.
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S. paucimobilis has been associated with a variety of infections in humans, including bacteremia, pneumonia, catheterrelated infections, meningitis, peritonitis, osteomyelitis, septic arthritis, postoperative endophthalmitis, lung empyema, splenic abscesses, urinary tract infections, and biliary tract infections. 3, 4, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] S. paucimobilis bacteremia occurs infrequently, but it has been encountered with increasing frequency in clinical settings. The only current publications discussing S. paucimobilis bacteremia are either isolated case reports or short series reports. In this study, we analyzed the clinical characteristics, manifestations, treatment, and clinical outcome of patients with S. paucimobilis bacteremia, identified both from E-Da hospital, Kaohsiung, Taiwan and the literature review. To the best of our knowledge, this is the largest case study of S. paucimobilis bacteremia to date.
Methods

Patient identification
This retrospective study was conducted at the E-Da hospital, a 1,000-bed hospital affiliated to I-Shou University in Southern Taiwan, and has been approved by the institutional review board of E-Da hospital (No. EMRP-097-026 
Results
A total of 16 patients who had positive blood cultures for S. paucimobilis were identified from our hospital during the study period. The median age of the patients was 54.0 years (range, 5 month-87 years; Table 1 ). In the literature search, 26 patients with S. paucimobilis bacteremia were identified. The median age of patients was 45.5 years (range, 10 days-82 years; Table 2 ).
3,4,9-21 Two cases were reported before 1980, two from 1981 to 1990, Combining cases from our patients with those from the literature, we found a total of 42 patients with positive blood cultures for S. paucimobilis. The median age was 48.5 years (range, 10 days-87 years) and 57.1% were male (Table 3) . Hospital-acquired bacteremia was identified in 69.0% of these patients (62.5% in our hospital and 73.1% in the literature). Of the 42 patients, 25 (59.5%) had indwelling intravenous devices. The most common comorbidities of these patients were malignancy (57.1%), followed by immunosuppressant use (40.5%). Other comorbidities included diabetes mellitus (11.9%), alcoholism (9.5%), liver cirrhosis (9.5%), end-stage renal disease (7.1%), chronic obstructive pulmonary disease (4.8%), burn injury (2.4%), and acquired immunodeficiency syndrome (2.4%). Primary S. paucimobilis bacteremia was found in 35.7% of patients. Catheter-related bloodstream infection was identified in 33.3% of patients, skin and soft tissue infection in 9.5%, pneumonia in 9.5%, urinary tract infection in 4.8%, biliary tract infection in 4.8%, and meningitis in 2.4%.
The antimicrobial susceptibility of blood isolates of S. paucimobilis from our hospital is summarized in In addition, treatment with fluoroquinolones or carbapenems was also reported in the literature. Of the 16 patients in our hospital, six (37.5%) received inappropriate initial empirical antibiotic therapy. The majority of patients, including those receiving inappropriate initial empirical antibiotic treatment at our hospital and patients from the literature, recovered from S. paucimobilis bacteremia. However, three patients (7.4%) suffered septic shock, including one patient from our hospital and two patients from the literature.
Discussion
S. paucimobilis was initially implicated as the causative pathogen in an infectious leg ulcer, 2 but until recently was rarely encountered in clinical settings. However, sporadic case reports indicate that the incidence of infection has been increasing in recent years, and our hospital has identified 16 cases of S. paucimobilis bacteremia in the past 4 years. This suggests that S. paucimobilis may be an emerging infectious pathogen worthy of further attention. S. paucimobilis has been isolated from both natural and hospital environments. [5] [6] [7] [8] This ubiquitous distribution implicates S. paucimobilis in both hospital-and communitybased infections. Hospital-acquired infections accounted for 69.0% of patients with S. paucimobilis bacteremia in our survey. Most of these patients acquired the infection in the hospital setting secondary to the presence of indwelling intravascular devices. The nosocomial infections are similar to those caused by non-enteric Gram-negative bacilli from hospital water distribution systems which may result in severe infections in patients with underlying debilitating conditions or with indwelling devices. 31 Recurrent and cluster infections have also been reported. 19, 21 In our study, we did not type these strains so cannot be sure whether our patients represent an outbreak of a single clone. However, these hospital-acquired bacteremias occurred in different wards and at different times and we therefore propose that these infections are not part of a single outbreak. Bacteremia caused by Gram-negative bacteria frequently results in significant morbidity and mortality rates, especially in patients with nosocomial infections. However, S. paucimobilis strains have not been strongly associated with high morbidity or mortality. This survey revealed no deaths due to S. paucimobilis bacteremia, but three patients went into septic shock as a result of S. paucimobilis bacteremia. Several factors might contribute to the virulence of S. paucimobilis in human infections.
This organism was found to have a significantly different enzyme profile from that of other bacteria, which may contribute to its pathogenesis. 32 Additionally, the presence of atypical lipopolysaccharide constituents of the outer cellular membrane of S. paucimobilis that may correspond to the lipid A present in other Gram-negative bacteria, with the accompanying deficiency in endotoxin activity, has been proposed to explain the low virulence of S. paucimobilis. 33 Although S. paucimobilis may be considered including two patients with bone marrow transplantation and six patients with peripheral blood stem cell transplantation. DM = diabetes mellitus; ESRD = end-stage renal disease; COPD = chronic obstructive pulmonary disease; AIDS = acquired immunodeficiency syndrome; BMT = bone marrow transplantation; CR-BSI = catheter-related bloodstream infection; SSTI = skin and soft tissue infection; BTI = biliary tract infection; UTI = urinary tract infection. No standard method currently exists to determine the antibiotic susceptibility of S. paucimobilis and these data are therefore variable in the literature. Peel et al stated that the isolate of S. paucimobilis from a leg ulcer was susceptible to tetracycline, kanamycin, gentamicin, sulfamethoxazole, chloramphenicol, carbenicillin, and tobramycin, but resistant to ampicillin, cephalothin, streptomycin, and colistin, as determined by a disk diffusion method. 2 Slotnick et al used disk agar-diffusion testing and revealed that their isolates were sensitive to ampicillin, carben icillin, chloramphenicol, gentamicin, tobramycin, kana mycin, tetracycline, and cotrimoxazole, and resistant to cephalothin, polymyxin, and nalidixic acid. 4 Smalley et al determined antimicrobial susceptibility by a microbroth dilution method 34 and they reported that all of the isolated S. paucimobilis strains produced β-lactamase and were therefore resistant to the majority of cephalosporins and penicillins. Reina et al evaluated the minimal inhibitory concentration of four isolates and observed that all were susceptible to ciprofloxacin and norfloxacin, and they concluded that aminoglycosides and fluoroquinolones should be the clinical antibiotics of choice for S. paucimobilis infection in humans. 12 Recently, Kilic et al determined the susceptibility of S. paucimobilis to eight antimicrobial agents by E-test (AB BIODISK, Solna, Sweden) and found that all isolates were susceptible to trimethoprim-sulfamethoxazole, imipenem, meropenem, amikacin, cefotaxime, and piperacillin-tazobactam, but 33.3% (2/6 isolates) were resistant to ciprofloxacin and gentamicin. 21 The most effective antimicrobial agents for S. paucimobilis isolates in vitro in our patients were fluoroquinolones, β-lactam/β-lactamase inhibitor combinations, carbapenems, and aminoglycosides. Most of our patients received first-second-,or third generation cephalosporins or amoxicillin/ampicillin (with or without clavulanate/sulbactam), either combined with aminoglycosides or not, and they all survived S. paucimobilis infection, even after receiving inappropriate initial empirical antibiotics. The favorable outcome in our study may support the conclusion that S. paucimobilis has low virulence.
There are several limitations in our study. First of all, this is a retrospective study. The treatments administered depended on the physicians' choice. Although all patients survived, it is difficult to compare the effect of different antibiotic treatments. Moreover, since there are no interpretative standards for S. paucimobilis, a disk diffusion assay may not be reliable in determining susceptibility and as a treatment guide.
In conclusion, S. paucimobilis can cause a variety of infections in healthy as well as immunocompromised individuals. The prevalence of S. paucimobilis infection in humans seems to have increased in recent times. This organism is commonly associated with nosocomial infection, especially in patients with indwelling intravascular devices. Although S. paucimobilis is an organism of low clinical virulence, infection caused by this pathogen can lead to septic shock, particularly in immunocompromised patients. Therefore, its importance cannot be neglected. Further clinical research is required to characterize this increasingly frequent infection.
